Session Item

 Meningeoma is a common type of benign tumor that can be managed in several ways, ranging from close observation, surgical resection, and various types of radiation. We present here results from a 10-year experience treating meningiomas with a hypofractionated approach.

To define the rate of tumor control and factors associated with relief of symptoms and radiation-related complications after radiosurgery and  hypofractionated radiosurgery for patients with imaging defined intracranial meningiomas.We reviewed the charts of 48 patients treated with stereotactic radiosurgery (SRS) or hypofractionated stereotactic radiotherapy (SRT) from 2008 to 2018. A total of 37 (82%) patients had WHO Grade 1 disease and 11 (22 %) had Grade 2. Outcomes that were analyzed included local control rates and the rate and grade of any reported toxicity.

: only 34 Patients with 37 lesions, who underwent the follow-Up regiem, are enrolled in the restrospective anaylsis. Follow-Up mean was 40 months (12-120 months). 25/34 patients had surgery before the radiotherapy. 14 underwent SRS with a median dose of 13,5 and 20 recieved hypofractioned SBRT with a median dose of 26,4 (22-45Gy) in median 6,8 fractions (6-15 fractions). Local control at 2 and 5 years for all patients was 90% and 88%, respectively. No patient suffered from toxicity >1 CTC. 21/34 patients showed stable disease, while 6/34 patients showed partiell Remission. 7/34 patients with meingeomas WHO II showed progression in a median of 22 months (13- 48 months)

: Hypofractionated radiosurgery with a dose of appears to provide a high rate of tumor control and a low incidence of side effects for patients with imaging defined intracranial meningiomas